Haemonetics (HAE) Given Media Sentiment Score of 0.37

Media stories about Haemonetics (NYSE:HAE) have trended positive this week, according to AlphaOne Sentiment. AlphaOne, a service of Accern, identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Haemonetics earned a coverage optimism score of 0.37 on AlphaOne’s scale. AlphaOne also assigned headlines about the medical instruments supplier an impact score of 40 out of 100, meaning that recent media coverage is unlikely to have an impact on the company’s share price in the near term.

These are some of the news headlines that may have impacted Alpha One’s scoring:

Several research firms have recently issued reports on HAE. Zacks Investment Research raised shares of Haemonetics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 11th. TheStreet raised shares of Haemonetics from a “c” rating to a “b-” rating in a research note on Thursday, April 13th. Finally, Barrington Research downgraded shares of Haemonetics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, February 7th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. Haemonetics currently has an average rating of “Hold” and an average target price of $34.57.

Haemonetics (NYSE:HAE) traded down 0.39% during midday trading on Thursday, hitting $40.84. 229,582 shares of the stock traded hands. Haemonetics has a 52 week low of $25.98 and a 52 week high of $41.65. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of 130.06 and a beta of 0.92. The stock’s 50-day moving average price is $39.76 and its 200 day moving average price is $38.59.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Monday, February 6th. The medical instruments supplier reported $0.43 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.40 by $0.03. Haemonetics had a net margin of 1.79% and a return on equity of 10.51%. The business earned $227.80 million during the quarter, compared to analyst estimates of $220 million. During the same period in the prior year, the business earned $0.48 EPS. The company’s revenue for the quarter was down 2.4% on a year-over-year basis. On average, equities research analysts predict that Haemonetics will post $1.52 EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was published by WKRB News and is owned by of WKRB News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at http://www.wkrb13.com/markets/2065680/haemonetics-hae-given-media-sentiment-score-of-0-37.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

5 Day Chart for NYSE:HAE

This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2065680/haemonetics-hae-given-media-sentiment-score-of-0-37.html

Receive News & Ratings for Haemonetics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Co. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.